Nat. Biotechnol. 29, 676 (2011); published online 5 August 2011; corrected after print 7 February 2012
In the version of this article initially published, only “ovarian and small cell lung cancer” were said to be among Avastin's current FDA-approved uses. In the US, Avastin is currently approved for advanced colon, non-small cell lung, glioblastoma and kidney cancers. FDA withdrew Avastin's breast cancer approval in November 2011 (Nat. Biotechnol. 30, 6 (2012). The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0811-676c
Rights and permissions
About this article
Cite this article
Ratner, M. Correction: Corrigendum: FDA panel votes to pull Avastin in breast cancer, again. Nat Biotechnol 30, 193 (2012). https://doi.org/10.1038/nbt0212-193d
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt0212-193d
